Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
EJNMMI Research
Published in: EJNMMI Research 1/2021

Open Access 01-12-2021 | Astrocytoma | Original research

Correlation of 4′-[methyl-11C]-thiothymidine PET with Gd-enhanced and FLAIR MRI in patients with newly diagnosed glioma

Authors: Takashi Norikane, Katsuya Mitamura, Yuka Yamamoto, Yukito Maeda, Kenichi Tanaka, Tetsuhiro Hatakeyama, Keisuke Miyake, Jun Toyohara, Yoshihiro Nishiyama

Published in: EJNMMI Research | Issue 1/2021

Login to get access

Abstract

Purpose

To elucidate the biological association between tumor proliferation, tumor infiltration and neovascularization, we analyzed the association between volumetric information of 4′-[methyl-11C]thiothymidine (4DST) positron emission tomography (PET) and fluid-attenuated inversion recovery (FLAIR) and T1-weighted gadopentetate dimeglumine (Gd)-enhanced magnetic resonance imaging (MRI), in patients with newly diagnosed glioma.

Methods

A total of 23 patients with newly diagnosed glioma who underwent both 4DST PET/CT and Gd-enhanced MRI before therapy were available for a retrospective analysis of prospectively collected data. The maximum standardized uptake value (SUVmax) for tumor (T) and the mean SUV for normal contralateral hemisphere (N) were calculated, and the tumor-to-normal (T/N) ratio was determined. Proliferative tumor volume (PTV) from 4DST PET and the volume of Gd enhancement (GdV) and hyperintense region on FLAIR (FLAIRV) from MRI were calculated.

Results

All gliomas but 3 diffuse astrocytomas and one anaplastic astrocytoma had 4DST uptake and Gd enhancement on MRI. There was no significant difference between PTV and GdV although the exact edges of the tumor differed in each modality. The FLAIRV was significantly larger than PTV (P < 0.001). Significant correlations between PTV and GdV (ρ = 0.941, P < 0.001) and FLAIRV (ρ = 0.682, P < 0.001) were found.

Conclusion

These preliminary results indicate that tumor proliferation assessed by 4DST PET is closely associated with tumor-induced neovascularization determined by Gd-enhanced MRI in patients with newly diagnosed glioma.
Literature
1.
Costa A, Silvestrini R, Mochen C, Lequaglie C, Boracchi P, Faranda A, et al. P53 expression, DNA ploidy and S-phase cell fraction in operable locally advanced non-small-cell lung cancer. Br J Cancer. 1996;73:914–9.CrossRef
2.
Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology. 2004;231:305–32.CrossRef
3.
Hatakeyama T, Kawai N, Nishiyama Y, Yamamoto Y, Sasakawa Y, Ichikawa T, et al. 11C-methionine (MET) and 18F-fluorothymidine (FLT) PET in patients with newly diagnosed glioma. Eur J Nucl Med Mol Imaging. 2008;35:2009–17.CrossRef
4.
Yamamoto Y, Wong TZ, Turkington TG, Hawk TC, Reardon DA, Coleman RE. 3’-deoxy-3’-[F-18]fluorothymidine positron emission tomography in patients with recurrent glioblastoma multiforme: comparison with Gd-DTPA enhanced magnetic resonance imaging. Mol Imaging Biol. 2006;8:340–7.CrossRef
5.
Yamamoto Y, Ono Y, Aga F, Kawai N, Kudomi N, Nishiyama Y. Correlation of 18F-FLT uptake with tumor grade and Ki-67 immunohistochemistry in patients with newly diagnosed and recurrent gliomas. J Nucl Med. 2012;53:1911–5.CrossRef
6.
Ogawa T, Kawai N, Miyake K, Shinomiya A, Yamamoto Y, Nishiyama Y, et al. Diagnostic value of PET/CT with 11C-methionine (MET) and 18F-fluorothymidine (FLT) in newly diagnosed glioma based on the 2016 WHO classification. EJNMMI Res. 2020;10:44.CrossRef
7.
Toyohara J, Kumata K, Fukushi K, Irie T, Suzuki K. Evaluation of [methyl-14C]4′-thiothymidine for in vivo DNA synthesis imaging. J Nucl Med. 2006;47:1717–22.PubMed
8.
Tanaka K, Yamamoto Y, Maeda Y, Yamamoto H, Kudomi N, Kawai N, et al. Correlation of 4′-[methyl-11C]-thiothymidine uptake with Ki-67 immunohistochemistry and tumor grade in patients with newly diagnosed gliomas in comparison with 11C-methionine uptake. Ann Nucl Med. 2016;30:89–96.CrossRef
9.
Toyota Y, Miyake K, Kawai N, Hatakeyama T, Yamamoto Y, Toyohara J, et al. Comparison of 4′-[methyl-11C]thiothymidine (11C–4DST) and 3′-deoxy-3′-[18F]fluorothymidine (18F-FLT) PET/CT in human brain glioma imaging. EJNMMI Res. 2015;5:7.CrossRef
10.
Earnest F 4th, Kelly PJ, Scheithauer BW, Kall BA, Cascino TL, Ehman RL, et al. Cerebral astrocytomas: histopathologic correlation of MR and CT contrast enhancement with stereotactic biopsy. Radiology. 1988;166:823–7.CrossRef
11.
Chang PD, Malone HR, Bowden SG, Chow DS, Gill BJA, Ung TH, et al. A multiparametric model for mapping cellularity in glioblastoma using radiographically localized biopsies. AJNR Am J Neuroradiol. 2017;38:890–8.CrossRef
12.
Shukla G, Alexander GS, Bakas S, Nikam R, Talekar K, Palmer JD, et al. Advanced magnetic resonance imaging in glioblastoma: a review. Chin Clin Oncol. 2017;6:40.CrossRef
13.
la Fougère C, Suchorska B, Bartenstein P, Kreth FW, Tonn JC. Molecular imaging of gliomas with PET: opportunities and limitations. Neuro Oncol. 2011;13:806–19.CrossRef
14.
Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med. 2002;43:1210–7.PubMed
15.
Plotnik DA, Wu S, Linn GR, Yip FCT, Comandante NL, Krohn KA, Toyohara J, Schwartz JL. In vitro analysis of transport and metabolism of 4′-thiothymidine in human tumor cells. Nucl Med Biol. 2015;42:470–4.CrossRef
16.
Nowosielski M, DiFranco MD, Putzer D, Seiz M, Recheis W, Jacobs AH, et al. An intra-individual comparison of MRI, [18F]-FET and [18F]-FLT PET in patients with high-grade gliomas. PLoS ONE. 2014;23:e95830.CrossRef
17.
Nikaki A, Angelidis G, Efthimiadou R, Tsougos I, Valotassiou V, Fountas K, et al. 18F-fluorothymidine PET imaging in gliomas: an update. Ann Nucl Med. 2017;31:495–505.CrossRef
18.
Toyohara J, Nariai T, Sakata M, Oda K, Ishii K, Kawabe T, et al. Whole-body distribution and brain tumor imaging with 11C–4DST: a pilot study. J Nucl Med. 2011;52:1322–8.CrossRef
19.
20.
Schwarzenberg J, Czernin J, Cloughesy TF, Ellingson BM, Pope WB, Grogan T, et al. Treatment response evaluation using 18F-FDOPA PET in patients with recurrent malignant glioma on bevacizumab therapy. Clin Cancer Res. 2014;20:3550–9.CrossRef
Metadata
Title
Correlation of 4′-[methyl-11C]-thiothymidine PET with Gd-enhanced and FLAIR MRI in patients with newly diagnosed glioma
Authors
Takashi Norikane
Katsuya Mitamura
Yuka Yamamoto
Yukito Maeda
Kenichi Tanaka
Tetsuhiro Hatakeyama
Keisuke Miyake
Jun Toyohara
Yoshihiro Nishiyama
Publication date
01-12-2021
Publisher
Springer Berlin Heidelberg
Published in
EJNMMI Research / Issue 1/2021
Electronic ISSN: 2191-219X
DOI
https://doi.org/10.1186/s13550-021-00785-8

Other articles of this Issue 1/2021

EJNMMI Research 1/2021 Go to the issue

Original research

Post-reconstruction enhancement of [18F]FDG PET images with a convolutional neural network

Original research

Automated liver lesion detection in 68Ga DOTATATE PET/CT using a deep fully convolutional neural network

Short communication

Correlation of in vivo imaging to morphomolecular pathology in translational research: challenge accepted

Original research

First experiences with 177Lu-PSMA-617 therapy for recurrent or metastatic salivary gland cancer

Original research

Carotid plaque inflammatory activity assessed by 2-[18F]FDG-PET imaging decrease after a neurological thromboembolic event

Original research

Feasibility of equivalent performance of 3D TOF [18F]-FDG PET/CT with reduced acquisition time using clinical and semiquantitative parameters